Purpose: We have applied intracavitary hyperthermo-radiotherapy to the treatment of various cancers. In this study, early response and acute reaction were analyzed. Methods: Eighteen patients treated with intracavitary hyperthermo-radiotherapy were as follows; 4 of esophageal cancer, 6 of uterine cervical cancer, 3 of rectal cancer, and 5 of others. Intracavitary hyperthermia was performed with Endoradiotherm 100A (OLYMPUS) once or twice a week with a total number of heating sessions ranging from 2 to 12 times. The heating was started just after the irradiation, and the temperature measured at the surface of applicator was kept at 42-44°C during the treatment for 30-40 min. External irradiation was performed in the majority of these 18 patients. Results: 9 cases achieved complete response (CR), 6 cases did partial response (PR) and 3 cases were no change (NC). Of CR 9 cases, 6 cases showed 2-year local control.
Introduction
Hyperthermia is an effective modality in cancer treatment1). However, for deep seated tumors it is difficult to obtain a rising of intratumor temperature using an external radio-frequency (RF) capacitive heating system. Thus, an intracavitary hyperthermia system was developed for the treatment of deep seated tumors2).
We thought that an inoperable deep seated tumor was difficult to control by radiation therapy alone and that a deep seated tumor was difficult to obtain a rising of intratumor temperature using external hyperthermia system. We have used intracavitary hyperthermo-radiotherapy to treat various inoperable cancers. In this study, we examined early response, local control rate, and acute reaction following the cessation of treatment. We also investigated which tumor sites were most suitable for intracavitary hyperthermia.
Materials and Methods
Patient characteristics are summarized in Table I One patient with esophageal cancer was treated in combination with chemotherapy consisting of CBDCA 100 mg (a total dose of 1,000 mg) with a schedule of weekly intravenous administration.
Results

Early response
Results are summarized in Table III . Complete response (CR), partial Response (PR), and no change (NC) was achieved in 9, 6, and 3 patients, respectively. In overall, the early response rate for the patients treated in this series was 83.3% (15/18).
Primary site including to regional lymph node There were 5 CR and 1 PR for the uterine cervix; 1 CR and 1 PR for the vagina; 2 CR and 2 PR for the esophagus; 1 CR and 2 NC for the rectum; 1 PR for the ovary; 1 PR and 1 NC for the other site. CR rate for the uterine cervix was 83% (5/6), for the vagina was 50% (1/2), for the esophagus was 50% (2/4), for the rectum was 33% (1/3). Patients with carcinoma of the ovary or other primary sites did not have CR.
Early response rates for the uterine cervix, vagina, and esophagus were better than for other primary sites.
There were 2 CR and 2 PR for lymph node metastasis in 4 cases with Ni lymph node metastasis. Early response rates for lymph node metastasis was similar to for primary site.
Heating site There were 4 CR, 1 PR, and 2 NC for the vaginal stump; 2 CR and 1 PR for the cervix; 2 CR and 2 PR for the esophagus; 1 CR for the rectum; and 2 PR and 1 NC for the other heating site. CR rates for the vaginal stump was 57% (4/7), for the uterine cervix was 67% (2/3), for the esophagus was 50% (2/4), for the rectum was 100% (1/1). Early response rates for vaginal stump, uterine cervix, and esophagus were better than other heating sites.
Histology There were 6 CR, 5 PR, and 1 NC for squamous cell carcinoma; 3 CR, 1 PR, and 2 NC for adenocarcinoma. CR rate for squamous cell carcinoma was 50% (6/12) and for adenocarcinoma was 50% (3/6). There was no difference in CR rate between these two groups. Number of heating sessions There were 4 CR, 1 PR, and 2 NC among patients who underwent with less than 5 heating sessions; and 5 CR, 5 PR, and 1 NC among patients who did with 5 or more heating sessions. CR rates among patients underwent less than with 5 heating sessions was 67% (4/6) and among patients who did with 5 or more heating sessions was 45% (5/11). There was no difference in CR rate between these two groups.
Radiation dose
There were 2 CR, 2 PR, and 2 NC among patients who received a dose of less than 50 Gy; and 7 CR, 4 PR, and 1 NC among patients who did a dose of 50 Gy or more. CR rates of patients who received a dose of less than 50 Gy was 33% (2/6), of patients who did a dose of 50 Gy or more was 58% (7/12). Early response rates of patients who received a dose of 50 Gy or more was better than one who did a dose less than 50 Gy. Regrowth free survival Fig. 1 shows the regrowth free survival curve obtained by the Kaplan-Meier method. For CR cases, the regrowth free survival rate was 75% both at 2 years and 5 years. It was significantly better than for PR cases. In 9 CR cases, 7 were well controlled without recurrence. In 6 PR cases, 3 were persistent without tumor regrowth. Of CR 9 cases, 6 cases showed 2-year local control. There were 2 esophageal tumors, 1 cervical tumor, and 1 vaginal stump tumor among 2-year local control cases.
Survival rate Fig. 2 shows the cumulative survival curve obtained by the Kaplan-Meier method. The overall survival at 2 years and 5 years was 64% and 39%, respectively. Seven patients died, 4 patients have survived without cancer, and 7 did with cancer. Pain during treatment was evaluated according to four categories: none , no pain; mild, pain that did not require the treatment; moderate, pain that could be treated with a narcotic analgesic; severe , pain that required discontinuation of the treatment. With respect to heating site , pain was severe and moderate in 7 cases for vaginal stump, 2 for cervix, and 1 for rectum. Pain during the treatment was greater in the pelvis than other regions.
2) Mucositis
Ulcerative lesions were observed in 2 cases at the vaginal stump . Mucositis was more severe at the vaginal stump than at other sites.
Late complication
Treatment-associated rectal bleeding was observed in 2 patients at 6 months. Both patients underwent the combined treatment with high dose rate intracavitary brachytherapy. Rectal surface dose ranged from 10 Gy to 25 Gy. One patient required surgery.
Discussion
In recent years, the advantages and disadvantages of hyperthermia for the treatment of malignant tumors have been more clearly defined due to an improvement of hyperthemic equipment, greater understanding of the biology involved, and clinical experiences".
It has often been reported that pain during the heating and skin damage cause discontinuation of the heating or present difficulties during elevation of tumor temperature, especially in the treatment for deep seated tumors using an RF capacitive heating system4). This situation has been improved from a development of various heating systems, including itracavitary hyperthermia equipment .
Sugimachi et al. reported a good response for esophageal cancer treated by intracavitary hyperthermia5
). An applicator for cervical cancer was developed by Hosoi et al. and this applicator is used clinically6) .
Hasegawa et al. reported that intracavitary hyperthermia was effective for the treatment of cervical cancer7) .
Our results showed a good response for the cervix, and esophagus in a view of primary sites , and for vaginal stump and esophagus in heating sites. Our results are similar to those of previous studies8)9).
There was no difference in local control rate with respect to tumor histology. The local control rate was affected by the number of heating sessions, and was possibly correlated with radiation dose. These results are in agreement with those of previous sutdiesm10-12).
Of the 9 CR cases, only 2 had local recurrence. This result indicates that hyperthermia contributes to obtain a local control.
In our study, heating sites that showed good response were the esophagus and vaginal stump . For the esophagus, the T4 case showed a poor response, but the T2 case showed a good response.
Concerning the heating device, the OLYMPUS Endoradiotherm 100A RF heating system dose not have the power to treat large tumor. Therefore, the depth treated with hyperthermia was limited to shallow layer .
Urahashi et al. and Sugimachi et al. reported that the heating depth of this system ranged from 7 mm to 9 mm13)14). Thus, intracavitary hyperthermia was considered to be more effective for lesions or sites that were ( 14 ) hyperthermo-radiotherapy •E J. Kawamori et al. accessible to the heating system. In our study, the lesions most accessible to the intracavitary hyperthermia system were vaginal stump tumor and esophageal tumor with a stage of less than T3.
Recently, concurrent combination brachytherapy and intracavitary hyperthermia for the treatment of esophageal cancer has attempted; the results will be interest 15).
In this study, pain during the heating for intracavitary hyperthermia was slightly more severe than that reported for external local hyperthermia16-18). However, the pain during the heating at the pelvic region was particularly less severe for intracavitary hyperthermia than for external local hyperthermia; this is an advantage of intracavitary hyperthermia.
Two patients who underwent sequential combination intracavitary hyperthermia and brachytherapy experienced rectal bleeding after 6 month, and one patients required salvage surgery. This result indicates that combination large dose radiation brachytherapy and intracavitary hyperthermia may increase the possibility of late normal tissue complication.
Conclusion
A good early response had been achieved by intracavitary hyperthermo-radiotherapy for esophageal cancer and stump tumor in gynecological cancer. It was considered that the advantages of intracavitary hyperthermia might be the reliability of heating for the treatment of localized tumors.
